Status:

ACTIVE_NOT_RECRUITING

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Lead Sponsor:

Pfizer

Conditions:

Duchenne Muscular Dystrophy

Eligibility:

MALE

4-7 years

Phase:

PHASE3

Brief Summary

The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. T...

Detailed Description

The study will assess the efficacy of PF-06939926 gene therapy on ambulatory function while also monitoring its safety. Approximately 99 boys with DMD will be enrolled and randomly assigned to one of ...

Eligibility Criteria

Inclusion

  • Key inclusion criteria:
  • Confirmed diagnosis of Duchenne muscular dystrophy by prior genetic testing
  • Receiving a stable daily dose (at least 0.5 mg/kg/day prednisone or prednisolone, or at least 0.75 mg/kg/day deflazacort) for at least 3 months prior to Screening
  • Ambulatory, as assessed by protocol-specified criteria
  • Key exclusion criteria:
  • Positive test performed by Pfizer for neutralizing antibodies to AAV9
  • Any treatment designed to increase dystrophin expression within 6 months prior to screening (e.g., Translarna™, EXONDYS 51™, VYONDYS 53™)
  • Any prior treatment with gene therapy
  • Any non-healed injury that may impact functional testing (eg NSAA)
  • Abnormality in specified laboratory tests, including blood counts, liver and kidney function
  • Any of the following genetic abnormalities in the dystrophin gene:
  • Any mutation (exon deletion, exon duplication, insertion, or point mutation) affecting any exon between exon 9 and exon 13, inclusive; OR
  • A deletion that affects both exon 29 and exon 30;OR
  • A deletion that affects any exons between 56-71, inclusive.

Exclusion

    Key Trial Info

    Start Date :

    November 5 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 15 2039

    Estimated Enrollment :

    114 Patients enrolled

    Trial Details

    Trial ID

    NCT04281485

    Start Date

    November 5 2020

    End Date

    April 15 2039

    Last Update

    January 2 2026

    Active Locations (53)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 14 (53 locations)

    1

    Arkansas Children's Hospital

    Little Rock, Arkansas, United States, 72202

    2

    Arkansas Children's

    Little Rock, Arkansas, United States, 72202

    3

    UCLA Medical Center

    Los Angeles, California, United States, 90095

    4

    University of Florida

    Gainesville, Florida, United States, 32610